GSK plc vs Johnson & Johnson — Stock Comparison
GSK plc (GSK) and Johnson & Johnson (JNJ) are both listed on US exchanges. This page compares their Q·Score ratings, key fundamentals (P/E, margins, growth), and Wall Street analyst consensus side by side. Data sourced from Yahoo Finance and updated on each page load.
Johnson & Johnson scores ahead of GSK plc on Q·Score (7.1 vs 6.3 out of 10), led by Sentiment (6.9 vs 3.3) and Quality (9.3 vs 8.5). GSK plc scores higher on Growth, reflecting stronger revenue and earnings momentum. Analyst price targets imply similar upside for both: +11.8% for GSK and +10.7% for JNJ.
Price Performance
Normalised to 100 at period start — shows relative performance.
Q·Score Breakdown
High-quality business with 41% return on equity and 18% profit margins.
⚠ cautious analyst consensus — few Buy ratings.
High-quality business with 26% return on equity and 22% profit margins.
⚠ earnings contracting 53% year-over-year.
Analyst Consensus
Fundamentals
Frequently Asked Questions
GSK vs JNJ: which stock scores better overall?
Based on Q·Score, Johnson & Johnson (JNJ) scores 7.1/10 versus GSK plc (GSK) at 6.3/10. The Q·Score measures five dimensions: Quality, Health, Growth, Valuation, and Sentiment. For informational purposes only — not financial advice.
Which has better revenue growth: GSK or JNJ?
GSK plc (GSK) scores higher on Growth (5.8/10 vs 5.1/10). GSK plc reports revenue growth (1.5% YoY) while Johnson & Johnson reports (9.9% YoY). Growth scores reflect revenue and earnings momentum relative to sector peers.
Is GSK or JNJ more attractively valued?
Johnson & Johnson (JNJ) scores higher on Valuation (7.3/10 vs 7/10). GSK trades at 9.7× P/E versus JNJ at 18.0×. Valuation is assessed using P/E ratio, analyst price targets, and 52-week range positioning relative to sector peers.
What do analysts say about GSK vs JNJ?
There are 7 analysts covering GSK with a consensus price target of $56.63, and 23 analysts covering JNJ with a consensus target of $252.87. Analyst consensus ratings are aggregated from Wall Street research and do not constitute investment advice.
Which is more profitable: GSK or JNJ?
Johnson & Johnson (JNJ) scores higher on Quality (9.3/10 vs 8.5/10). Net profit margin: GSK at 17.8%, JNJ at 21.8%. Quality scores reflect profit margins, return on equity, and free cash flow generation.
Which has stronger financial health: GSK or JNJ?
Johnson & Johnson (JNJ) scores higher on Financial Health (6.5/10 vs 5.8/10). Market beta: GSK at 0.29, JNJ at 0.26. Health scores consider beta, debt-to-equity, and current ratio. All investments carry risk — this is not investment advice.
What are the market caps of GSK and JNJ?
GSK plc (GSK) has a market capitalisation of $101.5B, while Johnson & Johnson (JNJ) has a market cap of $549.8B. Market cap data is sourced from Yahoo Finance and reflects the most recent available figures.
Related Comparisons
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →